Skip to main content
. 2016 Oct 24;44(11-12):1168–1182. doi: 10.1111/apt.13833

Table 1.

Compounds being developed for the treatment of NASH by targeting the gut immune system

Compound Description Pre‐clinical data Human triala
Liver‐extracted proteins Fatty liver‐derived proteins +77
Anti‐CD3 Anti‐CD3 antibodies +76 +119
PRX106 Anti TNF fusion protein +124 +a, 83
Imm124E Anti‐LPS antibodies +109 +123
Glycosphingolipids Glucosylceramide +90, 91, 92 +125
DR‐MP Delayed‐release mercaptopurine +a, 72
OS M1 Soy‐derived extracts +102
a

Tested for other indications.